FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386112430> ?p ?o ?g. }

• W4386112430 endingPage "31" @default.
• W4386112430 startingPage "20" @default.
• W4386112430 abstract "To determine the impact on overall survival (OS) and patient-reported outcomes (PROs) of combining atezolizumab with standard therapy for newly diagnosed stage III/IV ovarian cancer.The placebo-controlled double-blind randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial (NCT03038100) assigned eligible patients to 3-weekly atezolizumab 1200 mg or placebo for 22 cycles with platinum-based chemotherapy and bevacizumab. Coprimary endpoints were progression-free survival (already reported) and OS in the PD-L1-positive and intent-to-treat (ITT) populations, tested hierarchically. Prespecified PRO analyses focused on disease-related abdominal pain and bloating symptoms (European Organisation for Research and Treatment of Cancer QLQ-OV28), functioning, and health-related quality of life (HRQoL) (QLQ-C30).After 38 months' median follow-up, the OS hazard ratio in the PD-L1-positive population was 0.83 (95% CI, 0.66-1.06; p = 0.13); median OS was not estimable with atezolizumab versus 49.2 months with placebo. The hazard ratio for OS in the ITT population was 0.92 (95% CI, 0.78-1.09; median 50.5 versus 46.6 months, respectively). At week 9, similar proportions of patients in both arms of the neoadjuvant cohort showed ≥10-point improvement from baseline in abdominal pain and bloating, functioning, and HRQoL. In the primary surgery cohort, similar proportions of patients in each arm had improved, stable, or worsened physical and role function and HRQoL from baseline over time. Neither cohort showed differences between arms in treatment-related symptoms or overall side-effect bother.Incorporation of atezolizumab into standard therapy for newly diagnosed ovarian cancer does not significantly improve efficacy or impose additional treatment burden for patients.gov registration: NCT03038100." @default.
• W4386112430 created "2023-08-24" @default.
• W4386112430 creator A5002555374 @default.
• W4386112430 creator A5005227457 @default.
• W4386112430 creator A5008545738 @default.
• W4386112430 creator A5013784225 @default.
• W4386112430 creator A5015984427 @default.
• W4386112430 creator A5021769842 @default.
• W4386112430 creator A5024155502 @default.
• W4386112430 creator A5044923347 @default.
• W4386112430 creator A5054602117 @default.
• W4386112430 creator A5056037326 @default.
• W4386112430 creator A5058244284 @default.
• W4386112430 creator A5058422827 @default.
• W4386112430 creator A5059622280 @default.
• W4386112430 creator A5063224965 @default.
• W4386112430 creator A5067490446 @default.
• W4386112430 creator A5068335479 @default.
• W4386112430 creator A5069036306 @default.
• W4386112430 creator A5069337573 @default.
• W4386112430 creator A5072225627 @default.
• W4386112430 creator A5080157873 @default.
• W4386112430 creator A5081022486 @default.
• W4386112430 creator A5083659627 @default.
• W4386112430 creator A5089955620 @default.
• W4386112430 creator A5090765165 @default.
• W4386112430 creator A5091066647 @default.
• W4386112430 date "2023-10-01" @default.
• W4386112430 modified "2023-10-14" @default.
• W4386112430 title "Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer" @default.
• W4386112430 cites W2017915615 @default.
• W4386112430 cites W2041130945 @default.
• W4386112430 cites W2114725749 @default.
• W4386112430 cites W2132483348 @default.
• W4386112430 cites W2142353844 @default.
• W4386112430 cites W2325508296 @default.
• W4386112430 cites W2609577908 @default.
• W4386112430 cites W2767785601 @default.
• W4386112430 cites W2951714360 @default.
• W4386112430 cites W2962985284 @default.
• W4386112430 cites W3153473864 @default.
• W4386112430 cites W3169849224 @default.
• W4386112430 cites W3200231835 @default.
• W4386112430 cites W4212784899 @default.
• W4386112430 cites W4213122829 @default.
• W4386112430 cites W4226407945 @default.
• W4386112430 cites W4287730147 @default.
• W4386112430 cites W4296007111 @default.
• W4386112430 cites W4306666058 @default.
• W4386112430 cites W4313453870 @default.
• W4386112430 cites W4321749678 @default.
• W4386112430 cites W4377115689 @default.
• W4386112430 cites W4386244514 @default.
• W4386112430 doi "https://doi.org/10.1016/j.ygyno.2023.06.018" @default.
• W4386112430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37625235" @default.
• W4386112430 hasPublicationYear "2023" @default.
• W4386112430 type Work @default.
• W4386112430 citedByCount "0" @default.
• W4386112430 crossrefType "journal-article" @default.
• W4386112430 hasAuthorship W4386112430A5002555374 @default.
• W4386112430 hasAuthorship W4386112430A5005227457 @default.
• W4386112430 hasAuthorship W4386112430A5008545738 @default.
• W4386112430 hasAuthorship W4386112430A5013784225 @default.
• W4386112430 hasAuthorship W4386112430A5015984427 @default.
• W4386112430 hasAuthorship W4386112430A5021769842 @default.
• W4386112430 hasAuthorship W4386112430A5024155502 @default.
• W4386112430 hasAuthorship W4386112430A5044923347 @default.
• W4386112430 hasAuthorship W4386112430A5054602117 @default.
• W4386112430 hasAuthorship W4386112430A5056037326 @default.
• W4386112430 hasAuthorship W4386112430A5058244284 @default.
• W4386112430 hasAuthorship W4386112430A5058422827 @default.
• W4386112430 hasAuthorship W4386112430A5059622280 @default.
• W4386112430 hasAuthorship W4386112430A5063224965 @default.
• W4386112430 hasAuthorship W4386112430A5067490446 @default.
• W4386112430 hasAuthorship W4386112430A5068335479 @default.
• W4386112430 hasAuthorship W4386112430A5069036306 @default.
• W4386112430 hasAuthorship W4386112430A5069337573 @default.
• W4386112430 hasAuthorship W4386112430A5072225627 @default.
• W4386112430 hasAuthorship W4386112430A5080157873 @default.
• W4386112430 hasAuthorship W4386112430A5081022486 @default.
• W4386112430 hasAuthorship W4386112430A5083659627 @default.
• W4386112430 hasAuthorship W4386112430A5089955620 @default.
• W4386112430 hasAuthorship W4386112430A5090765165 @default.
• W4386112430 hasAuthorship W4386112430A5091066647 @default.
• W4386112430 hasConcept C121608353 @default.
• W4386112430 hasConcept C126322002 @default.
• W4386112430 hasConcept C141071460 @default.
• W4386112430 hasConcept C142724271 @default.
• W4386112430 hasConcept C159110408 @default.
• W4386112430 hasConcept C168563851 @default.
• W4386112430 hasConcept C203092338 @default.
• W4386112430 hasConcept C204787440 @default.
• W4386112430 hasConcept C207103383 @default.
• W4386112430 hasConcept C27081682 @default.
• W4386112430 hasConcept C2775949291 @default.
• W4386112430 hasConcept C2776956441 @default.
• W4386112430 hasConcept C2777701055 @default.
• W4386112430 hasConcept C2779951463 @default.

• next